Renal Transplant Recipients (RTRs) are at risk of developing osteoprosis and osteopenia due to underlying renal osteodystrophy, hypophosphatemia, and immunosupresstion. Which is more frequent in the first year after Renal Transplantation (RTX) that result in bone loss and fractures. The purpose of this study was to evaluate the effect of low dose intravenous pamidronate in prevention of early bone loss after RTX. We prospectively studied 40 (M=20, F=20) successfully RTRs with mean age of 38/05±13.93& mean BMI: 24.1±4.73& mean dialysis duration of 24.98±17.67 and assigned them in two age & sex match groups: Pamidronat treated (Pam) group received Vit D during the study &0.5 mg/kg intravenous Pamidronate at the time and one month after RTX & control group received only Vit D. We measured serum calcium, phosphate, Alkalin phosphatase, blood urea & creatinine at baseline & monthly and iPTH & BMD at baseline and 3 & 6 months after RTX. Lumbar BMD in Pam group increased significantly from 0.827±0.11 to0.857±0.12, (p<0.01) & decreased in control group from 0.900±0.16 to 0.812±0.11, (p<0.001) 6 month after RTX. There was also significant increase of Radius BMD (p<0.001) & non significant increase of Femor BMD in Pam & and significant decrease of BMD of Femor & Radius (p<0.001) in control group 6 month after RTX. T& Z score of Spine & Femor & Radius in month 6 after RTX significantly increased (p<0.001) in pam group & decreased in control group (p<0.001). After multivariant analysis there was significant correlation between Pamidronate & BMD of Spine, (r=0.3, p<0.001) but there was not any linear regression between age, sex, BMI, duration of dialysis & iPTH with BMD changes of Femor & Spine & Radius at month 6 in each groups. Intravenous Pamidronate is significantly useful in prevention of fast bone loss and can increase the BMD immediately after RTX.